Styryl-based compounds as potential in vivo imaging agents for beta-amyloid plaques
Qian Li1, Jaeki Min, Young-Hoon Ahn
1Department of Chemistry, New York University, School of Medicine, New York, NY 11219, USA.
Chembiochem : a European Journal of Chemical Biology
|August 21, 2007
Summary
Researchers developed new styryl-based compounds for imaging beta-amyloid plaques in Alzheimer's disease (AD). One compound, STB-8, showed excellent blood-brain barrier penetration and specific plaque staining in mouse models.
Area of Science:
- Neuroscience
- Medicinal Chemistry
- Biochemistry
Background:
- Beta-amyloid plaques are key pathological hallmarks of Alzheimer's disease (AD).
- Developing effective in vivo imaging agents for beta-amyloid plaques remains a significant challenge in AD research.
- Current imaging techniques may lack specificity or efficient blood-brain barrier (BBB) penetration.
Purpose of the Study:
- To synthesize and evaluate novel styryl-based neutral compounds as potential in vivo imaging agents for beta-amyloid plaques.
- To identify compounds with high binding affinity and specificity for beta-amyloid fibrils.
- To assess the performance of lead compounds in preclinical models of Alzheimer's disease.
Main Methods:
- Synthesis of a library of 56 styryl-based neutral compounds.
- In vitro evaluation of beta-amyloid plaque labeling in human AD brain sections.
- Determination of binding affinity to beta-amyloid fibrils using fluorescence intensity measurements.
- Ex vivo and in vivo imaging studies in an AD transgenic mouse model using the lead compound STB-8.
Main Results:
- 14 out of 56 synthesized compounds effectively labeled beta-amyloid plaques in vitro.
- A specific class of quinaldine-styryl scaffold compounds demonstrated significant binding affinity to beta-amyloid fibrils.
- The representative compound STB-8 exhibited excellent blood-brain barrier permeability.
- STB-8 successfully achieved specific staining of beta-amyloid plaques in vivo in an AD mouse model.
Conclusions:
- Styryl-based compounds, particularly those with a quinaldine-styryl scaffold, are promising candidates for beta-amyloid plaque imaging.
- STB-8 demonstrates potential as a diagnostic imaging agent for Alzheimer's disease due to its BBB permeability and plaque-specific targeting.
- Further investigation of STB-8 and related compounds could lead to improved diagnostic tools for Alzheimer's disease.
Related Concept Videos
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...